Ionic Liquid‐Reinforced Multifunctional Hydrogel for the Treatment of Enterocutaneous Fistula

J Jinjoo Kim H Hyeongseop Keum (The Laboratory for Patient‐Inspired Engineering Mayo Clinic 13400 East Shea Blvd. Scottsdale AZ 85259 USA) H Hassan Albadawi I Ismail Altinbasak (The Laboratory for Patient‐Inspired Engineering Mayo Clinic 13400 East Shea Blvd. Scottsdale AZ 85259 USA) F Furkan Yavuz (The Laboratory for Patient‐Inspired Engineering Mayo Clinic 13400 East Shea Blvd. Scottsdale AZ 85259 USA) E Erin H. Graf (Department of Laboratory Medicine and Pathology Mayo Clinic 5777 E Mayo Blvd. Phoenix AZ 85054 USA) N Nitin Mishra R Rahmi Oklu

Abstract

AbstractEnterocutaneous fistulas (ECFs) profoundly impact patients’ quality of life, contributing to high morbidity rates and increased mortality due to ineffective treatment options. To address this challenge, ECFGel, a multifunctional, tissue adhesive injectable hydrogel, designed to occlude, sterilize, and promote healing of ECF tracts, is developed. ECFGel is formulated using gelatin and oxidized dextran (O‐Dex) as base components, which form chemical crosslinks within the hydrogel and with surrounding biological tissues, ensuring tissue adhesiveness. A choline and geranate‐based ionic liquid (IL) is incorporated to provide dual functionality, potent antimicrobial activity, and mechanical enhancement. By optimizing IL concentration, ECFGel achieves rapid gelation, enhanced mechanical strength, and improved elastic recoverability. Additionally, iohexol (IOH) is added for radiopacity, enabling real‐time imaging and further strengthening the hydrogel's mechanical properties. ECFGel demonstrates antiswelling properties, biodegradability, and effective tract occlusion in porcine soft tissues. It shows strong antimicrobial activity against highly resistant, patient‐derived pathogens isolated from clinical ECF cases. In a porcine perianal fistula model, ECFGel enables rapid occlusion and complete healing, promoting tissue maturation, reducing bacterial load, and increasing markers of cell proliferation and vascularization compared to untreated controls. These promising results highlight ECFGel's potential as a new therapeutic option for treating infected ECFs.

Article Details

Volume / Issue Vol. 37, Issue 29
Published July 01, 2025
ISSN 0935-9648
Publisher Unknown Publisher

Journal Info

Advanced Materials

Unknown Publisher

ISSN: 0935-9648 Physical Sciences

Authors (8)

J

Jinjoo Kim

H

Hyeongseop Keum

The Laboratory for Patient‐Inspired Engineering Mayo Clinic 13400 East Shea Blvd. Scottsdale AZ 85259 USA

H

Hassan Albadawi

I

Ismail Altinbasak

The Laboratory for Patient‐Inspired Engineering Mayo Clinic 13400 East Shea Blvd. Scottsdale AZ 85259 USA

F

Furkan Yavuz

The Laboratory for Patient‐Inspired Engineering Mayo Clinic 13400 East Shea Blvd. Scottsdale AZ 85259 USA

E

Erin H. Graf

Department of Laboratory Medicine and Pathology Mayo Clinic 5777 E Mayo Blvd. Phoenix AZ 85054 USA

N

Nitin Mishra

R

Rahmi Oklu